To amend title XVIII of the Social Security Act to establish a medication evaluation and dispensing system for Medicare beneficiaries, to improve the quality of pharmaceutical services received by our Nation's elderly and disabled, and to reduce instances of adverse reactions to prescription drugs experienced by Medicare beneficiaries.
Medicare Medication Evaluation and Dispensing System Act of 1997 - Amends title XVIII (Medicare) of the Social Security Act to require the Secretary of Health and Human Services to establish and operate the Medicare Medication Evaluation and Dispensing System (MMEDS) to provide for: (1) prospective and retrospective review of prescription drugs furnished to Medicare beneficiaries; (2) education of physicians, patients, and pharmacists in the appropriate use of prescription drugs; (3) the establishment of standards for counseling Medicare beneficiaries regarding the appropriate use of prescription drugs; and (4) review, information, and counseling with respect to any prescription drug furnished to a Medicare beneficiary without regard to whether or not payment may be made for the drug under Medicare. Sets forth requirements for review of prescriptions.
Directs the Secretary to establish: (1) a point-of-sale electronic system for carriers and pharmacists to use in submitting information on outpatient prescription drugs dispensed to Medicare patients; and (2) standards to protect from public disclosure any MMEDS-provided information identifying individuals with respect to their physical or mental health.
Requires the Secretary to report to the Congress: (1) an analysis of the effect on net aggregate Medicare expenditures from the establishment of such a System; and (2) any recommendations on Medicare coverage of pharmacist professional services.
Directs the Secretary to publish and disseminate a consumer guide to outpatient prescription drugs to assist: (1) Medicare beneficiaries in reducing expenditures for them; and (2) individuals and entities furnishing items and services to such beneficiaries in determining the cost-effectiveness of such drugs.
Introduced in House
Introduced in House
Referred to House Ways and Means
Referred to the Committee on Ways and Means, and in addition to the Committee on Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to House Commerce
Sponsor introductory remarks on measure. (CR E547-548)
Referred to the Subcommittee on Health and Environment, for a period to be subsequently determined by the Chairman.
Sponsor introductory remarks on measure. (CR E810-811)
checking server…
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line